Spots Global Cancer Trial Database for hematology
Every month we try and update this database with for hematology cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Performance Evaluation Study | NCT04618848 | Hematology | Fingerstick blo... | 18 Years - | Sight Diagnostics | |
| A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components | NCT02549222 | Transfusion Rel... | Standard of Car... | - | Cerus Corporation | |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | NCT02017457 | Acute Myelogeno... Myelodysplastic... | Donor lymphocyt... Azacytidine | 18 Years - | University Hospital of Mont-Godinne | |
| A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer | NCT02507544 | Carcinoma Advanced Cancer | TRX-818 capsule... | 18 Years - | TaiRx, Inc. | |
| PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. | NCT02689622 | Myelodysplastic... | research of dis... research of com... physical perfor... | 70 Years - | University Hospital, Toulouse | |
| Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status | NCT02835937 | Red Blood Cell ... Anemia Hematology Oncology Ambulatory Care | No-Transfuse | 18 Years - | Mayo Clinic | |
| A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer | NCT02507544 | Carcinoma Advanced Cancer | TRX-818 capsule... | 18 Years - | TaiRx, Inc. | |
| Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia | NCT01380756 | Cancer Hematologic Mal... Leukemia Myeloid Leukemi... | Arm 1- Dose Esc... Arm 2- Dose Exp... | 18 Years - | Amgen | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO | NCT02149329 | Febrile Neutrop... Hematological M... | Discontinuation... | 18 Years - | Amsterdam UMC, location VUmc | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | NCT04243434 | Hematologic Dis... | Vincristine Sul... CHOP R-CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers | NCT02700360 | Chemotherapy-In... | high-fat diet EC-18 | 19 Years - 45 Years | Enzychem Lifesciences Corporation | |
| Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | NCT00276159 | Acute Lymphobla... Acute Myeloid L... Non-Hodgkin's L... Hodgkin's Lymph... Multiple Myelom... Chronic Lymphoc... | 852A | - | Masonic Cancer Center, University of Minnesota | |
| PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab | NCT01131247 | Chronic Lymphoc... | ofatumumab + be... | 18 Years - | Nevada Cancer Institute | |
| Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) | NCT00700206 | Myelodysplastic... | Ezatiostat Hydr... | 18 Years - | Telik | |
| Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO | NCT02149329 | Febrile Neutrop... Hematological M... | Discontinuation... | 18 Years - | Amsterdam UMC, location VUmc | |
| Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO | NCT02149329 | Febrile Neutrop... Hematological M... | Discontinuation... | 18 Years - | Amsterdam UMC, location VUmc | |
| Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers | NCT02532712 | Chemotherapy-In... | EC-18 Placebo | 19 Years - 45 Years | Enzychem Lifesciences Corporation | |
| Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors | NCT04450927 | Wide Spectrum o... Hematologic Dis... | 2 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients | NCT06133426 | Lymphoma, Non-H... Myeloma Multipl... | Connected scale... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT02834390 | Acute Myeloid L... | Quizartinib Cytarabine Idarubicin Daunorubicin | 20 Years - 75 Years | Daiichi Sankyo | |
| Tissue Microarray of Hematological Malignancies | NCT04142372 | Hematological M... | - | Tampere University Hospital | ||
| Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome | NCT01459159 | Myelodysplastic... | ezatiostat hydr... | 18 Years - | Telik | |
| Effects of NMES and Exercise in Hematological Cancer | NCT04755465 | Hematologic Mal... Muscle Weakness | Neuromuscular E... Structured Exer... | 18 Years - 65 Years | Acibadem University | |
| Pegfilgrastim PBPC Mobilization Study | NCT00066092 | Lymphoma Hodgkin's Lymph... Non-Hodgkin's L... Hematology Oncology | pegfilgrastim 1... filgrastim pegfilgrastim 6... | 18 Years - | Amgen | |
| Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY | NCT04268277 | Marginal Zone L... | Rituximab Pembrolizumab | 18 Years - | University of Ulm | |
| Better Leukemia Diagnostics Through AI (BELUGA) | NCT04466059 | Hematologic Mal... Leukemia Minimal Residua... Lymphoma Blood Cancer | Automated AI-Gu... | 18 Years - | Munich Leukemia Laboratory | |
| The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients | NCT04303091 | Multiple Myelom... Hematologic Neo... Advanced Cancer | Physical Activi... | 18 Years - | University of Calgary | |
| Integrative Medicine in Lymphoma Survivors | NCT05982223 | Lymphoma | Acupuncture Mind-body thera... Touch therapy Movement therap... Herbal suppleme... Emotional treat... | 18 Years - | Bnai Zion Medical Center | |
| AMG 319 Lymphoid Malignancy FIH | NCT01300026 | Cancer Chronic Lymphoc... Diffuse Large C... Hematologic Mal... Hematology Leukemia Low Grade Lymph... Lymphoma Mantle Cell Lym... Non-Hodgkin's L... Oncology Oncology Patien... T Cell Lymphoma Tumors | AMG 319 | 18 Years - | Amgen | |
| Performance Evaluation Study | NCT04618848 | Hematology | Fingerstick blo... | 18 Years - | Sight Diagnostics | |
| Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia | NCT04263480 | Waldenstrom Mac... | Carfilzomib + I... Ibrutinib | 18 Years - | University of Ulm | |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | NCT04243434 | Hematologic Dis... | Vincristine Sul... CHOP R-CHOP | 18 Years - | Acrotech Biopharma Inc. | |
| PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. | NCT02689622 | Myelodysplastic... | research of dis... research of com... physical perfor... | 70 Years - | University Hospital, Toulouse | |
| Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia | NCT04263480 | Waldenstrom Mac... | Carfilzomib + I... Ibrutinib | 18 Years - | University of Ulm | |
| Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia | NCT05130138 | Chronic Myeloid... | Pharmaceutical ... | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia | NCT05099471 | Waldenstrom Mac... | Venetoclax; Rit... DRC | 18 Years - | University of Ulm | |
| Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis | NCT01369498 | Myelofibrosis | Simtuzumab Ruxolitinib | 18 Years - | Gilead Sciences | |
| Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | NCT01519011 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | oral azacitidin... oral azacitidin... | 18 Years - | Celgene | |
| Onco-haematology Vigilance Card | NCT04931329 | Medical Oncolog... Hematology Molecular Targe... | - | University Hospital, Limoges | ||
| Velcade Consolidation Bone Study | NCT01286077 | Multiple Myelom... | bortezomib | 18 Years - | Janssen-Cilag International NV | |
| Onco-haematology Vigilance Card | NCT04931329 | Medical Oncolog... Hematology Molecular Targe... | - | University Hospital, Limoges | ||
| Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans | NCT01287923 | DLBCL | 18 Years - 70 Years | Rennes University Hospital | ||
| Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia | NCT05130138 | Chronic Myeloid... | Pharmaceutical ... | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Biomarkers in Multiple Myeloma | NCT05259553 | Hematological P... Newly Diagnosed... Chemotherapy | Blood samples | 18 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia | NCT00866762 | Polycythemia Ve... Essential Throm... | HDAC inhibitor ... | 18 Years - | Copenhagen University Hospital at Herlev | |
| Pegfilgrastim PBPC Mobilization Study | NCT00066092 | Lymphoma Hodgkin's Lymph... Non-Hodgkin's L... Hematology Oncology | pegfilgrastim 1... filgrastim pegfilgrastim 6... | 18 Years - | Amgen | |
| PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. | NCT02689622 | Myelodysplastic... | research of dis... research of com... physical perfor... | 70 Years - | University Hospital, Toulouse | |
| Better Leukemia Diagnostics Through AI (BELUGA) | NCT04466059 | Hematologic Mal... Leukemia Minimal Residua... Lymphoma Blood Cancer | Automated AI-Gu... | 18 Years - | Munich Leukemia Laboratory | |
| Correlation Between Ultrasound-assessed Quadriceps Muscle Mass and Baseline Whole-body Densitometry Muscle Index in the Post-cancer Population (JUMP Research II) | NCT06007794 | Cancer Post-cancer Hematology | JUMP group | 18 Years - 74 Years | Hospices Civils de Lyon | |
| Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? | NCT00892502 | Hematological D... Hematological M... Blood Diseases Malignant Lymph... Leukemia Multiple Myelom... | Bismuth tablets Placebo tablets | 18 Years - 75 Years | Copenhagen University Hospital at Herlev | |
| AMG 319 Lymphoid Malignancy FIH | NCT01300026 | Cancer Chronic Lymphoc... Diffuse Large C... Hematologic Mal... Hematology Leukemia Low Grade Lymph... Lymphoma Mantle Cell Lym... Non-Hodgkin's L... Oncology Oncology Patien... T Cell Lymphoma Tumors | AMG 319 | 18 Years - | Amgen | |
| Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD | NCT00908232 | Multiple Myelom... | Cyclophosphamid... Bortezomib Dexamethasone Lenalidomide | 18 Years - | Janssen-Cilag International NV | |
| Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) | NCT00700206 | Myelodysplastic... | Ezatiostat Hydr... | 18 Years - | Telik | |
| Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT02834390 | Acute Myeloid L... | Quizartinib Cytarabine Idarubicin Daunorubicin | 20 Years - 75 Years | Daiichi Sankyo | |
| Tissue Microarray of Hematological Malignancies | NCT04142372 | Hematological M... | - | Tampere University Hospital | ||
| Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | NCT00896454 | Breast Cancer Hypercalcemia o... Colon Cancer Endocrine Cance... Head and Neck C... Kidney Cancer Lung Cancer Lymphoma Metastatic Canc... Multiple Myelom... Parathyroid Neo... Renal Cancer Thyroid Cancer Hodgkin's Lymph... Non-Hodgkin's L... Non-Small Cell ... | denosumab | 18 Years - | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
